Tourmaline Bio Reports Loss as R&D Rises
Tourmaline Bio (NASDAQ:TRML), a clinical-stage biotechnology company focusing on treatments for inflammatory diseases, published its earnings for the second quarter on August 13, 2025. The most notable headline was the positive clinical milestone from its Phase 2 TRANQUILITY trial for its lead candidate, pacibekitug, in cardiovascular inflammation. Tourmaline reported a net loss per share (GAAP) of $0.90. There was no revenue, as expected for a pre-commercial biotech. Operating loss, however, widened compared to the prior year period. Overall, the period reflected solid pipeline momentum but highlighted the intensifying cash requirements as the company ramps into late-stage clinical development.
Source: Analyst estimates for the quarter provided by FactSet.
Tourmaline Bio is a biotechnology company developing novel treatments for inflammatory and autoimmune diseases. Its top priority is pacibekitug, an antibody targeting interleukin-6 (IL-6), a protein known to drive inflammation in cardiovascular and autoimmune conditions.
Source Fool.com
